These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24112553)

  • 1. Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.
    Shah SI; Cafferty FH; Langley RE; Abel PD
    J Sex Med; 2014 Jan; 11(1):314-5. PubMed ID: 24112553
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
    Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
    J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them.
    Bolla M
    Eur Urol; 2015 Nov; 68(5):909-10. PubMed ID: 26460877
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular toxicity of androgen deprivation therapy: a new door opens.
    Alibhai SM
    J Clin Oncol; 2011 Sep; 29(26):3500-2. PubMed ID: 21844507
    [No Abstract]   [Full Text] [Related]  

  • 6. Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels.
    Saad F
    Eur Urol; 2015 May; 67(5):837-8. PubMed ID: 25168615
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Mitsuzuka K; Arai Y
    Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
    Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Griebling TL
    J Urol; 2014 Jun; 191(6):1784-5. PubMed ID: 25280283
    [No Abstract]   [Full Text] [Related]  

  • 12. Limiting the adverse effects of androgen suppression.
    Prescrire Int; 2013 Jan; 22(134):21. PubMed ID: 23367680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease associated with androgen-deprivation therapy: time to give it due respect.
    Basaria S
    J Clin Oncol; 2015 Apr; 33(11):1232-4. PubMed ID: 25753444
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular risks of androgen deprivation therapy.
    Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
    Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Impact of androgen deprivation therapy on volume reduction and lower urinary tract symptoms in patients with prostate cancer.
    Shin YS; Lee DS
    Low Urin Tract Symptoms; 2020 Sep; 12(3):293-294. PubMed ID: 32924313
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Caubet JF
    J Natl Cancer Inst; 1999 Feb; 91(4):381-2. PubMed ID: 10050874
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
    Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
    J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Albertsen PC
    J Natl Cancer Inst; 1999 Apr; 91(7):646. PubMed ID: 10203286
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.
    Gardner JR; Livingston PM; Fraser SF
    J Clin Oncol; 2014 Feb; 32(4):335-46. PubMed ID: 24344218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis.
    Bigaran A; Zopf E; Gardner J; La Gerche A; Murphy DG; Howden EJ; Baker MK; Cormie P
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):35-48. PubMed ID: 32860010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.